<DOC>
	<DOCNO>NCT01385423</DOCNO>
	<brief_summary>This single center , `` modified standard design '' dose escalation study design determine maximum tolerate , minimum efficacious dose ( MTD/MED ) IL-15 ( Intravenous Recombinant Human IL-15 ) incidence donor natural killer ( NK ) cell expansion day +14 give haploidentical donor NK cell patient relapse refractory acute myelogenous leukemia ( AML ) .</brief_summary>
	<brief_title>Haploidentical Donor Natural Killer Cell Infusion With IL-15 Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>Once MTD/MED IL-15 determine , cohort expand total 19 patient . The primary goal extend phase establish correlation clinical endpoint , CRp define leukemic clearance ( &lt; 5 % marrow blast peripheral blood blast ) neutrophil recovery without platelet recovery , vivo expansion . Patients achieve complete remission neutrophil recovery ( ANC &gt; 500 ) least 4 week consider allogeneic transplant prolong remission independent study . All patient , include go transplant , follow determine disease free survival , treatment related mortality , time relapse .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>≥ 18 year age Meets one follow disease criterion : Primary acute myelogenous leukemia ( AML ) induction failure : complete response ( CR ) 2 induction attempt Relapsed AML Secondary AML ( MDS treatmentrelated ) : CR 1 cycle standard induction therapy . For patient &gt; 60 year age 1 cycle standard chemotherapy require either follow met : relapse within 6 month last chemotherapy blast count &lt; 30 % within 10 day start protocol AML relapse &gt; 2 month transplant option donor lymphocyte infusion ( e.g . recipient autologous umbilical cord blood [ UCB ] transplant ) Patients prior central nervous system ( CNS ) involvement eligible provide treated cerebrospinal fluid ( CSF ) clear least 2 week prior enrollment . CNS therapy ( chemotherapy radiation ) continue medically indicate study treatment . Available related HLAhaploidentical donor ( 35 6 HLAA , B C ) Karnofsky Performance Status &gt; 50 % Adequate organ function define : Creatinine : ≤ 2.0 mg/dL Hepatic : Liver function test ( LFT 's ) &lt; 5 time upper limit institutional normal ( ULN ) Pulmonary Function : oxygen saturation ≥ 90 % room air pulmonary function &gt; 50 % correct DLCO FEV1 Testing require symptomatic prior know impairment . Cardiac Function : Ejection fraction ( EF ) ≥ 40 % , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormalities Able prednisone immunosuppressive medication least 3 day prior Natural Killer ( NK ) cell infusion ( exclude preparative regimen premedications ) Women child bear potential men partner child bear potential must agree use effective contraception therapy 4 month completion therapy . Voluntary write consent Biphenotypic acute leukemia Transplant &lt; 60 day prior study enrollment Pregnant breastfeed The agent use study include fall Pregnancy Category D know teratogenic potential . Women child bear potential must negative pregnancy test within 14 day study treatment start Active autoimmune disease History severe asthma , presently chronic medication ( history mild asthma require therapy eligible ) New progressive pulmonary infiltrates screen chest xray chest CT scan evaluate bronchoscopy , feasible . Infiltrates attribute infection must stable/improving ( associated clinical improvement ) 1 week appropriate therapy ( 4 week presume documented fungal infection ) . Surgical resection waif wait requirement . Uncontrolled bacterial viral infection chronic asymptomatic viral hepatitis allow Pleural effusion large enough detectable chest xray Known hypersensitivity study agent use Received investigational drug within 14 day enrollment Known active CNS involvement Criteria For Initial Donor Selection : Related donor ( sibling , parent , offspring , parent offspring HLA identical sibling ) 1475 year age At least 40 kilogram body weight In general good health determine evaluate medical provider HLAhaploidentical donor/recipient match ( low resolution ) Not pregnant Agree undergo donor viral screening panel Able willing undergo apheresis Voluntary write consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>natural killer cell</keyword>
	<keyword>haploidentical donor</keyword>
</DOC>